These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20848569)

  • 1. Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort.
    Owen SA; Lunt M; Hider SL; Bruce IN; Barton A; Thomson W
    Arthritis Rheum; 2010 Dec; 62(12):3827-9. PubMed ID: 20848569
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
    Dervieux T
    J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
    [No Abstract]   [Full Text] [Related]  

  • 4. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
    Ranganathan P; Eisen S; Yokoyama WM; McLeod HL
    Ann Rheum Dis; 2003 Jan; 62(1):4-9. PubMed ID: 12480661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis.
    Tian H; Cronstein BN
    Bull NYU Hosp Jt Dis; 2007; 65(3):168-73. PubMed ID: 17922664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Behrens F; Koehm M; Burkhardt H
    Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update.
    Ling SF; Bluett J
    Pharmacogenomics; 2020 Jan; 21(1):3-6. PubMed ID: 31849277
    [No Abstract]   [Full Text] [Related]  

  • 11. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
    Wessels JA; van der Kooij SM; le Cessie S; Kievit W; Barerra P; Allaart CF; Huizinga TW; Guchelaar HJ;
    Arthritis Rheum; 2007 Jun; 56(6):1765-75. PubMed ID: 17530705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methotrexate: mainstay of rheumatoid arthritis treatment].
    Jacobs JW; Bijlsma JW
    Ned Tijdschr Geneeskd; 2009; 153():A879. PubMed ID: 19785862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
    Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
    Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X
    Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
    Singer O; Gibofsky A
    Curr Opin Rheumatol; 2011 May; 23(3):288-92. PubMed ID: 21378570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race and methotrexate pharmacogenetics in rheumatoid arthritis.
    Ranganathan P; McLeod H
    J Rheumatol; 2010 May; 37(5):1064; author reply 1065. PubMed ID: 20439524
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?
    Stamp L; Roberts R; Kennedy M; Barclay M; O'Donnell J; Chapman P
    Biomed Pharmacother; 2006 Dec; 60(10):678-87. PubMed ID: 17071051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events in methotrexate-treated rheumatoid arthritis patients.
    Sandoval DM; Alarcón GS; Morgan SL
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():49-56. PubMed ID: 8535650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.